Drug information for RAPTIVA

Form Dosage Status Therapeutic Equivalence Active Ingred Ref. Sponsor Document
VIAL; SUBCUTANEOUS 125MG/VIAL Discontinued   EFALIZUMAB efalizumab GENENTECH 125075
2012-04-18 Other Important Information from FDA

2009-11-20 Medication Guide

2009-03-16 Letter

2009-03-16 Label

2008-10-23 Letter

2008-10-23 Letter

2005-06-16 Letter

2005-06-16 Label

2004-10-25 Review

2003-11-18 Letter

Drug Adverse Effects information for RAPTIVA

Role code Indications Reaction # Reports
SS BLOOD PRESSURE LYMPHADENOPATHY 1
SS BLOOD PRESSURE SQUAMOUS CELL CARCINOMA 1
SS PSORIASIS LYMPHADENOPATHY 2
SS PSORIASIS LYMPHOCYTOSIS 2
SS PSORIASIS MANTLE CELL LYMPHOMA 2
SS PSORIASIS SQUAMOUS CELL CARCINOMA 2
C PRODUCT USED FOR UNKNOWN INDICATION DRUG INEFFECTIVE 1
C PRODUCT USED FOR UNKNOWN INDICATION GAIT DISTURBANCE 1
C PRODUCT USED FOR UNKNOWN INDICATION INJECTION SITE PAIN 1
C PRODUCT USED FOR UNKNOWN INDICATION LYMPHOMA 1
C PRODUCT USED FOR UNKNOWN INDICATION METASTATIC RENAL CELL CARCINOMA 3
C PRODUCT USED FOR UNKNOWN INDICATION PAIN IN EXTREMITY 1
C PRODUCT USED FOR UNKNOWN INDICATION PSORIASIS 1
C PRODUCT USED FOR UNKNOWN INDICATION SCAR 1
C PRODUCT USED FOR UNKNOWN INDICATION SKIN FISSURES 1
C PRODUCT USED FOR UNKNOWN INDICATION STAPHYLOCOCCAL INFECTION 1
C PSORIASIS METASTATIC RENAL CELL CARCINOMA 1
C PSORIASIS PROSTATE CANCER 1
C PSORIASIS PSORIASIS 1
Ads by Google